텍사스의 자가면역질환 임상 시험
자가면역질환 관련 연구 22개가 텍사스 내 여러 지역에서 참여자를 모집하고 있습니다.
텍사스의 도시
공식 연구 텍스트(영어)
Two Arm, Double-blind, Phase III Study Assessing Efficacy and Safety of Ianalumab Versus Placebo, in Participants With Sjögren's Disease With High Symptom Burden
- Novel Research LLC, Bellaire
- Arthritis Care of Texas, Corpus Christi
- Precision Comprehensive Clinical Research Solutions, Euless
- 외 3개
피험자 모집 중3상
18세 이상 · 모든 성별 · 2026. 9. 28. 업데이트됨 · NCT07621809A Study of JADE101 in Participants With Immunoglobulin A Nephropathy
- Jade Clinical Site, Houston
피험자 모집 중2상
18세 ~ 60세 · 모든 성별 · 2026. 9. 25. 업데이트됨 · NCT07541287Testing an Immunotherapy Anti-cancer Drug, Nivolumab, for Advanced Cancers in Patients With Autoimmune Disorders, AIM-NIVO
- UT Southwestern Simmons Cancer Center - RedBird, Dallas
- UT Southwestern/Simmons Cancer Center-Dallas, Dallas
- UT Southwestern/Simmons Cancer Center-Fort Worth, Fort Worth
- 외 2개
피험자 모집 중1상
18세 이상 · 모든 성별 · 2026. 9. 23. 업데이트됨 · NCT03816345A Study of Mezagitamab in Adults With Chronic Primary Immune Thrombocytopenia
- Baylor College of Medicine, Houston
피험자 모집 중3상
18세 이상 · 모든 성별 · 2026. 9. 18. 업데이트됨 · NCT06722235RESET-Myositis: An Open-Label Study to Evaluate the Safety and Efficacy of CABA-201 in Subjects With Active Idiopathic Inflammatory Myopathy or Juvenile Idiopathic Inflammatory Myopathy
- University of Texas Southwestern Medical Center - Accepting Juvenile Patients, Dallas
- Houston Methodist Hospital - Accepting Adult Patients, Houston
- University of Texas MD Anderson Cancer Center - Accepting Adult Patients, Houston
피험자 모집 중2/3상
6세 ~ 75세 · 모든 성별 · 2026. 9. 17. 업데이트됨 · NCT06154252Ublituximab in Autoantibody Positive Immune Mediated Necrotizing Myopathy
- University of Texas - Houston, Houston
피험자 모집 중2상
18세 이상 · 모든 성별 · 2026. 9. 17. 업데이트됨 · NCT07103746A Follow-up Study of Mezagitamab in Adults With Chronic Primary Immune Thrombocytopenia
- Baylor College of Medicine, Houston
피험자 모집 중3상
18세 이상 · 모든 성별 · 2026. 9. 9. 업데이트됨 · NCT06948318A Study of the Efficacy and Safety of Belimumab in Adults With Interstitial Lung Disease Associated With Connective Tissue Disease
- GSK Investigational Site, Houston
- GSK Investigational Site, Temple
피험자 모집 중3상
18세 이상 · 모든 성별 · 2026. 9. 8. 업데이트됨 · NCT06572384RESET-SLE: A Phase 1/2 Open-Label Study to Evaluate the Safety and Efficacy of CABA-201 in Subjects With Active Systemic Lupus Erythematosus
- University of Texas MD Anderson Cancer Center, Houston
피험자 모집 중1/2상
18세 ~ 65세 · 모든 성별 · 2026. 8. 26. 업데이트됨 · NCT06121297Music-4-MS to Improve Cognition in People Living With Multiple Sclerosis: A Feasibility Study
- University of Texas at Austin, Austin
피험자 모집 중
18세 ~ 80세 · 모든 성별 · 2026. 8. 17. 업데이트됨 · NCT07759115Open-label Extension Study of Zigakibart in Adults With IgA Nephropathy.
- Dallas Renal Group, Dallas
- Dallas Renal Group, Dallas
- Nephro Asso North Illinois Indiana, Houston
피험자 모집 중3상
18세 ~ 100세 · 모든 성별 · 2026. 8. 17. 업데이트됨 · NCT06858319RESET-MG: A Study to Evaluate the Safety and Efficacy of CABA-201 in Participants With Generalized Myasthenia Gravis
- Baylor College of Medicine Neurology Department, Houston
- Houston Methodist Hospital, Houston
- University of Texas MD Anderson Cancer Center, Houston
피험자 모집 중1/2상
18세 ~ 70세 · 모든 성별 · 2026. 8. 13. 업데이트됨 · NCT06359041Remdesivir for the Treatment of Upper Respiratory Tract Infection Due to RSV in Immunocompromised Individuals
- MD Anderson Cancer Center, Houston
피험자 모집 중2상
18세 이상 · 모든 성별 · 2026. 8. 6. 업데이트됨 · NCT06817889A Study of Mavorixafor in Participants With Congenital and Acquired Primary Autoimmune and Idiopathic Chronic Neutropenic Disorders Who Are Experiencing Recurrent and/or Serious Infections
- UT Southwestern Medical Center, Dallas
- Cook Children's Medical Center, Fort Worth
- Texas Children's Hospital/ Baylor College of Medicine, Houston
- 외 1개
피험자 모집 중3상
12세 이상 · 모든 성별 · 2026. 8. 6. 업데이트됨 · NCT06056297Study of BHV-1300 in Graves' Disease
- Site-109, Dallas
- Site-106, Houston
- Site-101, Houston
- 외 1개
피험자 모집 중1상
18세 ~ 65세 · 모든 성별 · 2026. 7. 31. 업데이트됨 · NCT06980649Study to Assess the Efficacy and Safety of IMVT-1402 in Participants With Mild to Severe Generalized Myasthenia Gravis
- Site Number - 1003, Dallas
- Site Number - 1047, Denton
- Site Number - 1057, Houston
- 외 1개
피험자 모집 중3상
18세 ~ 80세 · 모든 성별 · 2026. 7. 30. 업데이트됨 · NCT07039916KYSA-6: A Study of Anti-CD19 Chimeric Antigen Receptor T-Cell Therapy, in Patients With Generalized Myasthenia Gravis
- Houston Methodist Hospital, Houston
피험자 모집 중2/3상
18세 ~ 75세 · 모든 성별 · 2026. 7. 29. 업데이트됨 · NCT06193889A Multicenter Access and Distribution Protocol for Unlicensed Cryopreserved Cord Blood Units (CBUs)
- Medical City Dallas, Dallas
- Children's Medical Center Dallas, Dallas
- Zachary & Elizabeth Fisher Bone Marrow Transplant Program (Brooke Army Medical Center), Fort Sam Houston
- 외 5개
피험자 모집 중관찰 연구
전 연령 · 모든 성별 · 2026. 7. 6. 업데이트됨 · NCT01351545A Phase 1/2, Open-label, Safety and Dosing Study of Autologous CART Cells (Desmoglein 3 Chimeric Autoantibody Receptor T Cells [DSG3-CAART] or CD19-specific Chimeric Antigen Receptor T Cells [CABA-201]) in Subjects With Active, Pemphigus Vulgaris (RESET-PV)
- UT Southwestern Medical Center, Dept. of Dermatology, Dallas
- MD Anderson Texas Medical Center, Houston
피험자 모집 중1/2상
18세 이상 · 모든 성별 · 2026. 5. 29. 업데이트됨 · NCT04422912Testing of an Educational Tool for Patients With Melanoma and Pre-Existing Autoimmune Disease Who Are Candidates for Immune Checkpoint Inhibitors
- M D Anderson Cancer Center, Houston
피험자 모집 중관찰 연구
18세 이상 · 모든 성별 · 2026. 5. 20. 업데이트됨 · NCT04751396Phase I/II Study of AD-PluReceptor Plus Tafasitamab-cxix and Lymphodepleting Chemotherapy in Patients With Autoimmune Disorders
- MD Anderson Cancer Center, Houston
- The University of Texas Health Science Center at Houston, Houston
피험자 모집 중1/2상
18세 이상 · 모든 성별 · 2026. 4. 15. 업데이트됨 · NCT06434363A Phase 1 Study of Anitocabtagene Autoleucel for the Treatment of Subjects With Non-oncology Plasma Cell-related Diseases
- UT Southwestern Medical Center, Dallas
- Houston Methodist Hospital, Houston
피험자 모집 중1상
18세 이상 · 모든 성별 · 2026. 2. 25. 업데이트됨 · NCT06626919ClinicalTrials.gov 출처, 2026. 9. 30. 기준 데이터입니다. 각 연구는 자체적인 자격 기준을 설정하며, 연구 팀이 참여자를 결정합니다.